IT vs RXRX · P/E 16, rev $6.27B vs rev $58.8M
Gartner Inc (IT) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Gartner Inc (IT) is a information technology services company listed on US.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported IT revenue for 2024-12-31 was $6.27B. Net income was $1.25B. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. IT currently screens at market cap $11.03B and trailing P/E 16.3.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
IT currently screens at market cap $11.03B and trailing P/E 16.3. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the IT and RXRX stock pages for the full models.
Not investment advice.